ClinicalTrials.gg
Not yet recruitingNCT07617818Updated Jun 1, 2026

QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer

A Phase 2 interventional study of QL1706 + Cisplatin/Paclitaxel Neoadjuvant Therapy in Cervical Cancer, Neoadjuvant Therapy and Immunotherapy, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms — 9 open to participants now, 10 under way, 1 of them phase 3. Iparomlimab/Tuvonralimab · Uterine Cervical Neoplasms.

Planned enrollment
6th of 12
50 · median 50
Started
2026
with 1 other
Phase 2
11 of 12
8 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms, this one is the 6th largest by planned enrollment, is one of 2 that started in 2026, is one of 11 in phase 2, and was the 11th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

9 of the 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About Iparomlimab/Tuvonralimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of QL1706 combined with cisplatin and paclitaxel as neoadjuvant therapy in patients with FIGO 2018 stage IB1-IB3 cervical cancer undergoing conservative surgery.

The primary endpoint is pathological complete response (pCR). Secondary endpoints include objective response rate (ORR), progression-free survival (PFS), overall survival (OS), 3-year pelvic recurrence rate, and safety profile.

Additionally, exploratory biomarker analyses will be conducted to investigate changes in immune status, genomic alterations, PD-L1 expression, tumor mutational burden, MSI-H/dMMR status, and vaginal microbiota before and after treatment.

Read the detailed description

Cervical cancer remains one of the most common gynecologic malignancies worldwide. Neoadjuvant chemotherapy (NACT) has demonstrated favorable response rates in locally advanced cervical cancer; however, pathological complete response (pCR) rates remain limited.

QL1706 is a novel bifunctional PD-1/CTLA-4 antibody combination developed using the MabPair® platform. It consists of the anti-PD-1 antibody iparomlimab and the anti-CTLA-4 antibody tuvonralimab. Previous studies have demonstrated promising antitumor activity in recurrent or metastatic cervical cancer.

This study aims to investigate whether the addition of QL1706 to cisplatin/paclitaxel neoadjuvant therapy can improve pathological response and clinical outcomes in patients with FIGO 2018 stage IB1-IB3 cervical cancer undergoing conservative surgery.

Approximately 50 patients will be enrolled. Eligible patients will receive neoadjuvant QL1706 combined with cisplatin and paclitaxel followed by radical surgery. Efficacy will be evaluated using RECIST v1.1 and pathological assessment. Safety will be assessed according to CTCAE v5.0.

Exploratory translational studies will evaluate immune microenvironment changes, molecular biomarkers, and vaginal microbiota alterations associated with treatment response.

03

Conditions studied

  • Cervical Cancer
  • Neoadjuvant Therapy
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18-65 years.
  • confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
  • FIGO 2018 stage IB1, IB2, or IB3 cervical cancer.
  • Pelvic MRI completed before enrollment.
  • performance status of 0-2.
  • Adequate organ and bone marrow function.
  • No prior immunotherapy for malignant tumors.
  • Ability to understand and willingness to sign written .

Exclusion criteria

Exclusion Criteria:

  • Presence of uncontrolled concomitant .
  • Active disease or history of autoimmune disease with potential recurrence.
  • Interstitial lung disease or uncontrolled pneumonitis.
  • Active or infection.
  • Known infection.
  • Receipt of within 30 days before first dose.
  • Uncontrolled cardiovascular disease.
  • Known to study drugs.
  • Any condition that, in the investigator's judgment, may interfere with study participation or interpretation of results.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    QL1706 + Cisplatin/Paclitaxel Neoadjuvant Therapy

    Drug: QL1706 + Cisplatin/Paclitaxel Neoadjuvant Therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR)

    Proportion of patients achieving pathological complete response after neoadjuvant therapy.

    Time frame: At surgery following completion of neoadjuvant therapy

Secondary outcomes

  1. Objective Response Rate (ORR)

    Proportion of patients achieving complete or partial response according to RECIST v1.1.

    Time frame: During neoadjuvant treatment period

  2. Progression-Free Survival (PFS)

    Time from treatment initiation to disease progression or death.

    Time frame: Up to 3 years

  3. 3-Year Pelvic Recurrence Rate

    Proportion of patients with pelvic recurrence within 3 years.

    Time frame: 3 years

  4. Adverse Events

    Incidence and severity of adverse events graded according to CTCAE v5.0.

    Time frame: From informed consent through 30 days after last treatment dose

  5. Overall Survival (OS)

    Time from treatment initiation to death from any cause

    Time frame: Up to 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.

Of 155 non-industry phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 24 months is below that.

Counting every sponsor, half of 205 studies reached it within 42 months; a quarter within 29 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 1, 2026
StartEst.
Jun 15, 2026
Primary completionEst.
Jun 15, 2028
CompletionEst.
Dec 15, 2029
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07617818
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Jun 15, 2028 (estimated)
Completion
Dec 15, 2029 (estimated)
Last update
Jun 1, 2026

Study contacts

Zhigang Zhang, MD
Contact
zzg2011@zju.edu.cn
86057189713631
Jianwei Zhou, PhD
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iparomlimab/Tuvonralimab · Cisplatin · Paclitaxel

Start the discussion